Cyclacel Pharmaceuticals Inc.

10/23/2024 | Press release | Distributed by Public on 10/23/2024 07:29

Fadraciclib, an oral CDK2/9 inhibitor, in patients with advanced solid tumors and lymphoma with CDKN2A and/or CDKN2B genetic alterations

Read this content
Click here to read the original version at the source's official website. The text of this article is not available at the moment.